Lopinavir
Pyrimidinones
Ritonavir
HIV Protease Inhibitors
Anti-HIV Agents
HIV Infections
Drug Dosage Calculations
Plasma
Saquinavir
Antiretroviral Therapy, Highly Active
Viral Load
Drug Resistance, Viral
Drug Therapy, Combination
HIV-1
HIV Protease
Nelfinavir
Indinavir
Reverse Transcriptase Inhibitors
Drug Combinations
Carbamates
Drug Interactions
Pyridines
Area Under Curve
Drug Resistance, Multiple, Viral
Treatment Failure
CD4 Lymphocyte Count
Organophosphonates
Lamivudine
Tablets
Lipodystrophy
HIV
Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction. (1/326)
ABT-378 is a potent in vitro inhibitor of the HIV protease and is currently being developed for coadministration with another HIV protease inhibitor, ritonavir, as an oral therapeutic treatment for HIV infection. In the present study, the effect of ritonavir, a potent inhibitor of cytochrome P-450 (CYP) 3A, on the in vitro metabolism of ABT-378 was examined. Furthermore, the effect of ABT-378-ritonavir combinations on several CYP-dependent monooxygenase activities in human liver microsomes was also examined. ABT-378 was found to undergo NADPH- and CYP3A4/5-dependent metabolism to three major metabolites, M-1 (4-oxo) and M-3/M-4 (4-hydroxy epimers), as well as several minor oxidative metabolites in human liver microsomes. The mean apparent K(m) and V(max) values for the metabolism of ABT-378 by human liver microsomes were 6.8 +/- 3.6 microM and 9.4 +/- 5.5 nmol of ABT-378 metabolized/mg protein/min, respectively. Ritonavir inhibited human liver microsomal metabolism of ABT-378 potently (K(i) = 0.013 microM). The combination of ABT-378 and ritonavir was much weaker in inhibiting CYP-mediated biotransformations than ritonavir alone, and the inhibitory effect appears to be primarily due to the ritonavir component of the combination. The ABT-378-ritonavir combinations (at 3:1 and 29:1 ratios) inhibited CYP3A (IC(50) = 1.1 and 4.6 microM), albeit less potently than ritonavir (IC(50) = 0.14 microM). Metabolic reactions mediated by CYP1A2, CYP2A6, and CYP2E1 were not affected by the ABT-378-ritonavir combinations. The inhibitory effects of ABT-378-ritonavir combinations on CYP2B6 (IC(50) = >30 microM), CYP2C9 (IC(50) = 13.7 and 23.0 microM), CYP2C19 (IC(50) = 28.7 and 38.0 microM), and CYP2D6 (IC(50) = 13.5 and 29.0 microM) were marginal and are not likely to produce clinically significant drug-drug interactions. (+info)Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. (2/326)
The association of genotypic changes in human immunodeficiency virus (HIV) protease with reduced in vitro susceptibility to the new protease inhibitor lopinavir (previously ABT-378) was explored using a panel of viral isolates from subjects failing therapy with other protease inhibitors. Two statistical tests showed that specific mutations at 11 amino acid positions in protease (L10F/I/R/V, K20M/R, L24I, M46I/L, F53L, I54L/T/V, L63P, A71I/L/T/V, V82A/F/T, I84V, and L90M) were associated with reduced susceptibility. Mutations at positions 82, 54, 10, 63, 71, and 84 were most closely associated with relatively modest (4- and 10-fold) changes in phenotype, while the K20M/R and F53L mutations, in conjunction with multiple other mutations, were associated with >20- and >40-fold-reduced susceptibility, respectively. The median 50% inhibitory concentrations (IC(50)) of lopinavir against isolates with 0 to 3, 4 or 5, 6 or 7, and 8 to 10 of the above 11 mutations were 0.8-, 2.7-, 13.5-, and 44.0-fold higher, respectively, than the IC(50) against wild-type HIV. On average, the IC(50) of lopinavir increased by 1.74-fold per mutation in isolates containing three or more mutations. Each of the 16 viruses that displayed a >20-fold change in susceptibility contained mutations at residues 10, 54, 63, and 82 and/or 84, along with a median of three mutations at residues 20, 24, 46, 53, 71, and 90. The number of protease mutations from the 11 identified in these analyses (the lopinavir mutation score) may be useful for the interpretation of HIV genotypic resistance testing with respect to lopinavir-ritonavir (Kaletra) regimens and may provide insight into the genetic barrier to resistance to lopinavir-ritonavir in both antiretroviral therapy-naive and protease inhibitor-experienced patients. (+info)Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. (3/326)
The safety and antiviral activity of lopinavir (Lpv), a protease inhibitor (PI) coformulated with ritonavir (Rtv) to enhance its pharmacokinetic properties, were evaluated in 70 patients with plasma human immunodeficiency virus type 1 (HIV-1) RNA levels of 1000-100,000 copies/mL on a first PI-containing regimen. Patients were randomized to substitute only the PI with Lpv/Rtv, 400/100 mg or 400/200 mg twice daily. On day 15, nevirapine (200 mg 2x/day) was added, and nucleoside reverse-transcriptase inhibitors were changed. Despite a >4-fold reduction in phenotypic susceptibility to the preentry PI in 63% of patients, mean plasma HIV-1 RNA levels declined by 1.14 log(10) copies/mL after 2 weeks of Lpv/Rtv. At week 48, 86% of subjects receiving treatment had plasma HIV-1 RNA levels of <400 copies/mL; 76% had levels <50 HIV-1 RNA copies/mL (intent-to-treat: 70% and 60%, respectively). Mean CD4 cell counts increased by 125 cells/muL. Three patients discontinued therapy for drug-related adverse events. (+info)Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. (4/326)
A study was designed to determine the interactions, both clinical and pharmacokinetic, between methadone and lopinavir-ritonavir. Results demonstrated a 36% reduction in the methadone area under the plasma concentration-time curve after the introduction of lopinavir-ritonavir, with no coincident symptoms of opioid withdrawal and no requirement for methadone dose adjustment. (+info)Select HIV protease inhibitors alter bone and fat metabolism ex vivo. (5/326)
Human immunodeficiency virus (HIV) therapies have been associated with alterations in fat metabolism and bone mineral density. This study examined the effects of HIV protease inhibitors (PIs) on bone resorption, bone formation, and adipocyte differentiation using ex vivo cultured osteoclasts, osteoblasts, and adipocytes, respectively. Osteoclast activity, measured using a rat neonatal calvaria assay, increased in the presence of nelfinavir (NFV; 47.2%, p = 0.001), indinavir (34.6%, p = 0.001), saquinavir (24.3%, p = 0.001), or ritonavir (18%, p < 0.01). In contrast, lopinavir (LPV) and amprenavir did not increase osteoclast activity. In human mesenchymal stem cells (hMSCs), the PIs LPV and NFV decreased osteoblast alkaline phosphatase enzyme activity and gene expression significantly (p < 0.05). LPV and NFV diminished calcium deposition and osteoprotegrin expression (p < 0.05), whereas the other PIs investigated did not. Adipogenesis of hMSCs was strongly inhibited by saquinavir and NFV (>50%, p < 0.001) and moderately inhibited by ritonavir and LPV (>40%, p < 0.01). Expression of diacylglycerol transferase, a marker of adipocyte differentiation, decreased in hMSCs treated with NFV. Amprenavir and indinavir did not affect adipogenesis or lipolysis. These results suggest that bone and fat formation in hMSCs of bone marrow may be coordinately down-regulated by some but not all PIs. (+info)In vitro antiviral interaction of lopinavir with other protease inhibitors. (6/326)
The in vitro inhibition of wild-type human immunodeficiency virus (HIV) by combinations of lopinavir and six other protease inhibitors over a range of two-drug combination ratios was evaluated. Combinations of lopinavir with indinavir, nelfinavir, amprenavir, tipranavir, and BMS-232632 generally displayed an additive relationship. In contrast, a consistent, statistically significant synergistic inhibition of HIV type 1 replication with combinations of lopinavir and saquinavir was observed. Analysis of the combination indices indicated that lopinavir with saquinavir was synergistic over the entire range of drug combination ratios tested and at all levels of inhibition in excess of 40%. Cellular toxicity was not observed at the highest drug concentrations tested. These results suggest that administration of combinations of the appropriate dose of lopinavir with other protease inhibitors in vivo may result in enhanced antiviral activity with no associated increase in cellular cytotoxicity. More importantly, the observed in vitro synergy between lopinavir and saquinavir provides a theoretical basis for the clinical exploration of a novel regimen of lopinavir-ritonavir and saquinavir. (+info)Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. (7/326)
BACKGROUND: Lopinavir is a newly developed inhibitor of human immunodeficiency virus (HIV) protease that, when formulated with ritonavir, yields mean trough plasma lopinavir concentrations that are at least 75 times as high as that needed to inhibit replication of wild-type HIV by 50 percent. METHODS: We conducted a double-blind trial in which 653 HIV-infected adults who had not received antiretroviral therapy for more than 14 days were randomly assigned to receive either lopinavir-ritonavir (400 mg of lopinavir plus 100 mg of ritonavir twice daily) with nelfinavir placebo or nelfinavir (750 mg three times daily) with lopinavir-ritonavir placebo. All patients also received open-label stavudine and lamivudine. The primary efficacy end points were the presence of fewer than 400 HIV RNA copies per milliliter of plasma at week 24 and the time to the loss of virologic response through week 48. RESULTS: At week 48, greater proportions of patients treated with lopinavir-ritonavir than of patients treated with nelfinavir had fewer than 400 copies of HIV RNA per milliliter (75 percent vs. 63 percent, P<0.001) and fewer than 50 copies per milliliter (67 percent vs. 52 percent, P<0.001). The time to the loss of virologic response was greater in the lopinavir-ritonavir group than in the nelfinavir group (hazard ratio, 2.0; 95 percent confidence interval, 1.5 to 2.7; P<0.001). The estimated proportion of patients with a persistent virologic response through week 48 was 84 percent for patients receiving lopinavir-ritonavir and 66 percent for those receiving nelfinavir. Both regimens were well tolerated, with the rate of discontinuation related to the study drugs at 3.4 percent among patients receiving lopinavir-ritonavir and 3.7 percent among patients receiving nelfinavir. Among patients with more than 400 copies of HIV RNA per milliliter at some point from week 24 through week 48, resistance mutations in HIV protease were demonstrated in viral isolates from 25 of 76 nelfinavir-treated patients (33 percent) and none of 37 patients treated with lopinavir-ritonavir (P<0.001). CONCLUSIONS: For the initial treatment of HIV-infected adults, a combination regimen that includes lopinavir-ritonavir is well tolerated and has antiviral activity superior to that of a nelfinavir-containing regimen. (+info)Serious bradyarrhythmia that was possibly induced by lopinavir-ritonavir in 2 patients with acquired immunodeficiency syndrome. (8/326)
We describe 2 patients with acquired immunodeficiency syndrome who had potentially fatal bradyarrhythmia that occurred shortly after commencement of antiretroviral therapy. Lopinavir-ritonavir was the only drug that both patients were using. (+info)Lopinavir is an antiretroviral medication used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. It is a protease inhibitor, which works by blocking the action of protease, an enzyme that the virus needs to multiply. Lopinavir is often prescribed in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART). The medication is available under the brand name Kaletra, which is a fixed-dose combination of lopinavir and ritonavir.
It's important to note that while lopinavir can help manage HIV infection and reduce the risk of transmission, it does not cure the disease. Regular adherence to the medication regimen is necessary to maintain its effectiveness and prevent the development of drug-resistant strains of the virus.
Pyrimidinones are a class of heterocyclic organic compounds that contain a pyrimidine ring fused with a ketone group. The basic structure of a pyrimidinone consists of two nitrogen atoms and four carbon atoms in a six-membered ring, with a carbonyl (C=O) group attached to one of the carbon atoms.
In a medical context, pyrimidinones are important because many naturally occurring and synthetic compounds that contain this structure have been found to have biological activity. For example, some pyrimidinones have antiviral, antibacterial, or anticancer properties, making them useful in the development of new drugs for various medical conditions.
One well-known drug that contains a pyrimidinone ring is the antiviral medication Ribavirin, which is used to treat hepatitis C and certain viral hemorrhagic fevers. Other pyrimidinones are being studied for their potential therapeutic benefits in areas such as cancer therapy, neuroprotection, and inflammation.
Ritonavir is an antiretroviral medication used in the treatment and prevention of HIV/AIDS. It is a protease inhibitor, which works by blocking the action of protease, an enzyme that the virus needs to multiply. By doing this, Ritonavir helps to reduce the amount of HIV in the body, keeping it at a low level and preventing the disease from progressing.
Ritonavir is often used in combination with other antiretroviral drugs as part of highly active antiretroviral therapy (HAART). It is also sometimes used at lower doses to boost the levels of other protease inhibitors in the body, a practice known as "pharmacologic boosting."
It's important to note that Ritonavir does not cure HIV/AIDS, but it can help people with HIV live longer, healthier lives. As with all medications, Ritonavir can have side effects, and it may interact with other drugs, so it's important to take it exactly as prescribed by a healthcare provider.
HIV Protease Inhibitors are a class of antiretroviral medications used in the treatment of HIV infection. They work by blocking the activity of the HIV protease enzyme, which is necessary for the virus to replicate and infect new cells. By inhibiting this enzyme, the medication prevents the virus from maturing and assembling into new infectious particles.
HIV protease inhibitors are often used in combination with other antiretroviral drugs as part of a highly active antiretroviral therapy (HAART) regimen. This approach has been shown to effectively suppress viral replication, reduce the amount of virus in the bloodstream (viral load), and improve the health and longevity of people living with HIV.
Examples of HIV protease inhibitors include saquinavir, ritonavir, indinavir, nelfinavir, amprenavir, fosamprenavir, atazanavir, darunavir, and tipranavir. These medications are usually taken orally in the form of tablets or capsules, and may be prescribed alone or in combination with other antiretroviral drugs.
It is important to note that HIV protease inhibitors can have significant side effects, including gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as metabolic changes such as increased cholesterol and triglyceride levels. Therefore, regular monitoring of liver function, lipid levels, and other health parameters is necessary to ensure safe and effective use of these medications.
Anti-HIV agents are a class of medications specifically designed to treat HIV (Human Immunodeficiency Virus) infection. These drugs work by interfering with various stages of the HIV replication cycle, preventing the virus from infecting and killing CD4+ T cells, which are crucial for maintaining a healthy immune system.
There are several classes of anti-HIV agents, including:
1. Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs): These drugs act as faulty building blocks that the virus incorporates into its genetic material, causing the replication process to halt. Examples include zidovudine (AZT), lamivudine (3TC), and tenofovir.
2. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs): These medications bind directly to the reverse transcriptase enzyme, altering its shape and preventing it from functioning properly. Examples include efavirenz, nevirapine, and rilpivirine.
3. Protease Inhibitors (PIs): These drugs target the protease enzyme, which is responsible for cleaving viral polyproteins into functional components. By inhibiting this enzyme, PIs prevent the formation of mature, infectious virus particles. Examples include atazanavir, darunavir, and lopinavir.
4. Integrase Strand Transfer Inhibitors (INSTIs): These medications block the integrase enzyme, which is responsible for inserting the viral genetic material into the host cell's DNA. By inhibiting this step, INSTIs prevent the virus from establishing a permanent infection within the host cell. Examples include raltegravir, dolutegravir, and bictegravir.
5. Fusion/Entry Inhibitors: These drugs target different steps of the viral entry process, preventing HIV from infecting CD4+ T cells. Examples include enfuvirtide (T-20), maraviroc, and ibalizumab.
6. Post-Attachment Inhibitors: This class of medications prevents the virus from attaching to the host cell's receptors, thereby inhibiting infection. Currently, there is only one approved post-attachment inhibitor, fostemsavir.
Combination therapy using multiple classes of antiretroviral drugs has been shown to effectively suppress viral replication and improve clinical outcomes in people living with HIV. Regular adherence to the prescribed treatment regimen is crucial for maintaining an undetectable viral load and reducing the risk of transmission.
HIV (Human Immunodeficiency Virus) infection is a viral illness that progressively attacks and weakens the immune system, making individuals more susceptible to other infections and diseases. The virus primarily infects CD4+ T cells, a type of white blood cell essential for fighting off infections. Over time, as the number of these immune cells declines, the body becomes increasingly vulnerable to opportunistic infections and cancers.
HIV infection has three stages:
1. Acute HIV infection: This is the initial stage that occurs within 2-4 weeks after exposure to the virus. During this period, individuals may experience flu-like symptoms such as fever, fatigue, rash, swollen glands, and muscle aches. The virus replicates rapidly, and the viral load in the body is very high.
2. Chronic HIV infection (Clinical latency): This stage follows the acute infection and can last several years if left untreated. Although individuals may not show any symptoms during this phase, the virus continues to replicate at low levels, and the immune system gradually weakens. The viral load remains relatively stable, but the number of CD4+ T cells declines over time.
3. AIDS (Acquired Immunodeficiency Syndrome): This is the most advanced stage of HIV infection, characterized by a severely damaged immune system and numerous opportunistic infections or cancers. At this stage, the CD4+ T cell count drops below 200 cells/mm3 of blood.
It's important to note that with proper antiretroviral therapy (ART), individuals with HIV infection can effectively manage the virus, maintain a healthy immune system, and significantly reduce the risk of transmission to others. Early diagnosis and treatment are crucial for improving long-term health outcomes and reducing the spread of HIV.
Benzoxazines are a class of heterocyclic organic compounds that contain a benzene fused to an oxazine ring. They are known for their diverse chemical and pharmacological properties, including anti-inflammatory, antimicrobial, and antitumor activities. Some benzoxazines also exhibit potential as building blocks in the synthesis of pharmaceuticals and materials. However, it is important to note that specific medical definitions for individual compounds within this class may vary depending on their unique structures and properties.
Drug dosage calculations refer to the process of determining the appropriate amount of a medication that should be administered to a patient, based on various factors such as the patient's weight, age, kidney and liver function, and the route of administration. The calculation is crucial to ensure that the patient receives a safe and effective dose, neither too much nor too little.
The formula used to calculate drug dosages may vary depending on the medication and the route of administration. For instance, the dosage for intravenous (IV) medications may be calculated based on the patient's body surface area, while oral medications may be dosed based on weight or age.
Accurate drug dosage calculations require a solid understanding of mathematical principles, as well as knowledge of the medication being administered and the patient's individual health status. Healthcare professionals, such as nurses, pharmacists, and physicians, are trained to perform these calculations and must adhere to strict protocols to minimize errors and ensure patient safety.
In the context of medicine, plasma refers to the clear, yellowish fluid that is the liquid component of blood. It's composed of water, enzymes, hormones, antibodies, clotting factors, and other proteins. Plasma serves as a transport medium for cells, nutrients, waste products, gases, and other substances throughout the body. Additionally, it plays a crucial role in the immune response and helps regulate various bodily functions.
Plasma can be collected from blood donors and processed into various therapeutic products, such as clotting factors for people with hemophilia or immunoglobulins for patients with immune deficiencies. This process is called plasma fractionation.
Saquinavir is an antiretroviral medication used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. It is a type of protease inhibitor, which works by blocking the action of protease, an enzyme that the virus needs to multiply. By inhibiting this enzyme, saquinavir helps prevent the virus from replicating and slows down the progression of HIV to AIDS (Acquired Immunodeficiency Syndrome).
Saquinavir is often used in combination with other antiretroviral drugs as part of a highly active antiretroviral therapy (HAART) regimen. It is important to note that saquinavir does not cure HIV or AIDS, but it can help reduce the amount of virus in the body and improve the immune system function, reducing the risk of opportunistic infections and other complications associated with HIV/AIDS.
As with any medication, saquinavir can have side effects, including gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as headaches, rash, and elevated liver enzymes. It is essential to take saquinavir exactly as prescribed by a healthcare provider and to report any side effects or changes in health status promptly.
A capsule is a type of solid pharmaceutical dosage form in which the drug is enclosed in a small shell or container, usually composed of gelatin or other suitable material. The shell serves to protect the drug from degradation, improve its stability and shelf life, and facilitate swallowing by making it easier to consume. Capsules come in various sizes and colors and can contain one or more drugs in powder, liquid, or solid form. They are typically administered orally but can also be used for other routes of administration, such as rectal or vaginal.
Antiretroviral Therapy, Highly Active (HAART) is a medical treatment regimen used to manage HIV infection. It involves the combination of three or more antiretroviral drugs from at least two different classes, aiming to maximally suppress viral replication and prevent the development of drug resistance. The goal of HAART is to reduce the amount of HIV in the body to undetectable levels, preserve immune function, and improve quality of life for people living with HIV. Commonly used antiretroviral classes include nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inhibitors (INSTIs), and fusion inhibitors.
Viral load refers to the amount or quantity of virus (like HIV, Hepatitis C, SARS-CoV-2) present in an individual's blood or bodily fluids. It is often expressed as the number of virus copies per milliliter of blood or fluid. Monitoring viral load is important in managing and treating certain viral infections, as a higher viral load may indicate increased infectivity, disease progression, or response to treatment.
Drug resistance, viral, refers to the ability of a virus to continue replicating in the presence of antiviral drugs that are designed to inhibit or stop its growth. This occurs when the virus mutates and changes its genetic makeup in such a way that the drug can no longer effectively bind to and inhibit the function of its target protein, allowing the virus to continue infecting host cells and causing disease.
Viral drug resistance can develop due to several factors, including:
1. Mutations in the viral genome that alter the structure or function of the drug's target protein.
2. Changes in the expression levels or location of the drug's target protein within the virus-infected cell.
3. Activation of alternative pathways that allow the virus to replicate despite the presence of the drug.
4. Increased efflux of the drug from the virus-infected cell, reducing its intracellular concentration and effectiveness.
Viral drug resistance is a significant concern in the treatment of viral infections such as HIV, hepatitis B and C, herpes simplex virus, and influenza. It can lead to reduced treatment efficacy, increased risk of treatment failure, and the need for more toxic or expensive drugs. Therefore, it is essential to monitor viral drug resistance during treatment and adjust therapy accordingly to ensure optimal outcomes.
Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.
In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:
1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.
Examples of combination drug therapy include:
1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.
When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.
HIV-1 (Human Immunodeficiency Virus type 1) is a species of the retrovirus genus that causes acquired immunodeficiency syndrome (AIDS). It is primarily transmitted through sexual contact, exposure to infected blood or blood products, and from mother to child during pregnancy, childbirth, or breastfeeding. HIV-1 infects vital cells in the human immune system, such as CD4+ T cells, macrophages, and dendritic cells, leading to a decline in their numbers and weakening of the immune response over time. This results in the individual becoming susceptible to various opportunistic infections and cancers that ultimately cause death if left untreated. HIV-1 is the most prevalent form of HIV worldwide and has been identified as the causative agent of the global AIDS pandemic.
HIV Protease is a crucial enzyme that plays a significant role in the replication cycle of the Human Immunodeficiency Virus (HIV). It is responsible for cleaving or cutting specific long protein chains, produced during the translation of viral RNA, into smaller functional proteins. These proteins are essential for the formation of new virus particles.
The HIV Protease enzyme functions like a pair of molecular scissors, recognizing and cutting particular amino acid sequences in these polyprotein chains. By inhibiting this enzyme's activity with antiretroviral drugs known as protease inhibitors, the production of mature, infectious viral particles can be effectively prevented, which is a crucial component of highly active antiretroviral therapy (HAART) for managing HIV infection and reducing the risk of transmitting the virus to others.
Nelfinavir is a medication that belongs to a class of antiretroviral drugs called protease inhibitors. It is used in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). Nelfinavir works by blocking the activity of HIV protease, an enzyme that is necessary for the replication of the virus. By inhibiting this enzyme, nelfinavir prevents the virus from multiplying and thus slows down the progression of the disease.
Here's a medical definition of Nelfinavir:
"Nelfinavir mesylate is a synthetic peptidomimetic inhibitor of the HIV-1 protease, an enzyme essential for the processing of viral gag and gag-pol polyproteins, reverse transcriptase, and integrase. Nelfinavir is used in combination with other antiretroviral agents for the treatment of HIV infection and AIDS."
It's important to note that nelfinavir is not a cure for HIV or AIDS, but it can help manage the disease by reducing the amount of virus in the body and improving the immune system function. As with any medication, nelfinavir has potential side effects and risks, so it should be taken under the guidance and supervision of a healthcare provider.
Indinavir is an antiretroviral medication used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. It belongs to a class of drugs known as protease inhibitors, which work by blocking the action of protease enzymes that are necessary for the HIV virus to replicate. By inhibiting this process, indinavir helps prevent the spread of HIV in the body and reduces the risk of developing AIDS (Acquired Immunodeficiency Syndrome).
Indinavir is often prescribed as part of a combination therapy regimen with other antiretroviral drugs. It is available in capsule form and is typically taken several times a day, usually on an empty stomach. As with all medications, indinavir can have side effects, which may include nausea, diarrhea, headache, and changes in liver function. Regular monitoring of blood tests is necessary to ensure that the drug is working effectively and not causing any harmful side effects.
It's important to note that while antiretroviral therapy can help manage HIV infection and improve quality of life, it does not cure the disease. Therefore, it is essential for individuals with HIV to continue taking their medications as prescribed and to follow up regularly with their healthcare provider.
Reverse Transcriptase Inhibitors (RTIs) are a class of antiretroviral drugs that are primarily used in the treatment and management of HIV (Human Immunodeficiency Virus) infection. They work by inhibiting the reverse transcriptase enzyme, which is essential for the replication of HIV.
HIV is a retrovirus, meaning it has an RNA genome and uses a unique enzyme called reverse transcriptase to convert its RNA into DNA. This process is necessary for the virus to integrate into the host cell's genome and replicate. Reverse Transcriptase Inhibitors interfere with this process by binding to the reverse transcriptase enzyme, preventing it from converting the viral RNA into DNA.
RTIs can be further divided into two categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs are analogs of the building blocks of DNA, which get incorporated into the growing DNA chain during replication, causing termination of the chain. NNRTIs bind directly to the reverse transcriptase enzyme, causing a conformational change that prevents it from functioning.
By inhibiting the reverse transcriptase enzyme, RTIs can prevent the virus from replicating and reduce the viral load in an infected individual, thereby slowing down the progression of HIV infection and AIDS (Acquired Immunodeficiency Syndrome).
A drug combination refers to the use of two or more drugs in combination for the treatment of a single medical condition or disease. The rationale behind using drug combinations is to achieve a therapeutic effect that is superior to that obtained with any single agent alone, through various mechanisms such as:
* Complementary modes of action: When different drugs target different aspects of the disease process, their combined effects may be greater than either drug used alone.
* Synergistic interactions: In some cases, the combination of two or more drugs can result in a greater-than-additive effect, where the total response is greater than the sum of the individual responses to each drug.
* Antagonism of adverse effects: Sometimes, the use of one drug can mitigate the side effects of another, allowing for higher doses or longer durations of therapy.
Examples of drug combinations include:
* Highly active antiretroviral therapy (HAART) for HIV infection, which typically involves a combination of three or more antiretroviral drugs to suppress viral replication and prevent the development of drug resistance.
* Chemotherapy regimens for cancer treatment, where combinations of cytotoxic agents are used to target different stages of the cell cycle and increase the likelihood of tumor cell death.
* Fixed-dose combination products, such as those used in the treatment of hypertension or type 2 diabetes, which combine two or more active ingredients into a single formulation for ease of administration and improved adherence to therapy.
However, it's important to note that drug combinations can also increase the risk of adverse effects, drug-drug interactions, and medication errors. Therefore, careful consideration should be given to the selection of appropriate drugs, dosing regimens, and monitoring parameters when using drug combinations in clinical practice.
Carbamates are a group of organic compounds that contain the carbamate functional group, which is a carbon atom double-bonded to oxygen and single-bonded to a nitrogen atom (> N-C=O). In the context of pharmaceuticals and agriculture, carbamates are a class of drugs and pesticides that have carbamate as their core structure.
Carbamate insecticides work by inhibiting the enzyme acetylcholinesterase, which is responsible for breaking down the neurotransmitter acetylcholine in the synapses of the nervous system. When this enzyme is inhibited, acetylcholine accumulates in the synaptic cleft, leading to overstimulation of the nervous system and ultimately causing paralysis and death in insects.
Carbamate drugs are used for a variety of medical indications, including as anticonvulsants, muscle relaxants, and psychotropic medications. They work by modulating various neurotransmitter systems in the brain, such as GABA, glutamate, and dopamine. Carbamates can also be used as anti- parasitic agents, such as ivermectin, which is effective against a range of parasites including nematodes, arthropods, and some protozoa.
It's important to note that carbamate pesticides can be toxic to non-target organisms, including humans, if not used properly. Therefore, it's essential to follow all safety guidelines when handling or using these products.
A drug interaction is the effect of combining two or more drugs, or a drug and another substance (such as food or alcohol), which can alter the effectiveness or side effects of one or both of the substances. These interactions can be categorized as follows:
1. Pharmacodynamic interactions: These occur when two or more drugs act on the same target organ or receptor, leading to an additive, synergistic, or antagonistic effect. For example, taking a sedative and an antihistamine together can result in increased drowsiness due to their combined depressant effects on the central nervous system.
2. Pharmacokinetic interactions: These occur when one drug affects the absorption, distribution, metabolism, or excretion of another drug. For example, taking certain antibiotics with grapefruit juice can increase the concentration of the antibiotic in the bloodstream, leading to potential toxicity.
3. Food-drug interactions: Some drugs may interact with specific foods, affecting their absorption, metabolism, or excretion. An example is the interaction between warfarin (a blood thinner) and green leafy vegetables, which can increase the risk of bleeding due to enhanced vitamin K absorption from the vegetables.
4. Drug-herb interactions: Some herbal supplements may interact with medications, leading to altered drug levels or increased side effects. For instance, St. John's Wort can decrease the effectiveness of certain antidepressants and oral contraceptives by inducing their metabolism.
5. Drug-alcohol interactions: Alcohol can interact with various medications, causing additive sedative effects, impaired judgment, or increased risk of liver damage. For example, combining alcohol with benzodiazepines or opioids can lead to dangerous levels of sedation and respiratory depression.
It is essential for healthcare providers and patients to be aware of potential drug interactions to minimize adverse effects and optimize treatment outcomes.
I'm sorry for any confusion, but "Pyridines" is not a medical term. It is a chemical term that refers to a class of organic compounds with the chemical structure of a six-membered ring containing one nitrogen atom and five carbon atoms (heterocyclic aromatic compound).
In a biological or medical context, pyridine derivatives can be found in various natural and synthetic substances. For example, some medications contain pyridine rings as part of their chemical structure. However, "Pyridines" itself is not a medical term or condition.
The term "Area Under Curve" (AUC) is commonly used in the medical field, particularly in the analysis of diagnostic tests or pharmacokinetic studies. The AUC refers to the mathematical calculation of the area between a curve and the x-axis in a graph, typically representing a concentration-time profile.
In the context of diagnostic tests, the AUC is used to evaluate the performance of a test by measuring the entire two-dimensional area underneath the receiver operating characteristic (ROC) curve, which plots the true positive rate (sensitivity) against the false positive rate (1-specificity) at various threshold settings. The AUC ranges from 0 to 1, where a higher AUC indicates better test performance:
* An AUC of 0.5 suggests that the test is no better than chance.
* An AUC between 0.7 and 0.8 implies moderate accuracy.
* An AUC between 0.8 and 0.9 indicates high accuracy.
* An AUC greater than 0.9 signifies very high accuracy.
In pharmacokinetic studies, the AUC is used to assess drug exposure over time by calculating the area under a plasma concentration-time curve (AUC(0-t) or AUC(0-\∞)) following drug administration. This value can help determine dosing regimens and evaluate potential drug interactions:
* AUC(0-t): Represents the area under the plasma concentration-time curve from time zero to the last measurable concentration (t).
* AUC(0-\∞): Refers to the area under the plasma concentration-time curve from time zero to infinity, which estimates total drug exposure.
Multiple drug resistance (MDR) in viruses refers to the ability of a virus to resist or inhibit the effects of multiple antiviral agents. This occurs when a virus mutates and develops mechanisms that prevent antiviral drugs from effectively binding to their target sites, rendering the drugs unable to suppress viral replication.
In the context of virology, "multiple" typically means resistance to at least three or more classes of antiviral drugs. This is a significant concern in the management of viral infections such as HIV, HCV, and influenza, where MDR can lead to reduced treatment options, increased risk of disease progression, and potential transmission of resistant strains. Regular monitoring and appropriate use of antiviral agents are crucial for preventing and managing multiple drug resistance in viruses.
Treatment failure is a term used in medicine to describe the situation when a prescribed treatment or intervention is not achieving the desired therapeutic goals or objectives. This may occur due to various reasons, such as:
1. Development of drug resistance by the pathogen or disease being treated.
2. Inadequate dosage or frequency of the medication.
3. Poor adherence or compliance to the treatment regimen by the patient.
4. The presence of underlying conditions or comorbidities that may affect the efficacy of the treatment.
5. The severity or progression of the disease despite appropriate treatment.
When treatment failure occurs, healthcare providers may need to reassess the patient's condition and modify the treatment plan accordingly, which may include adjusting the dosage, changing the medication, adding new medications, or considering alternative treatments.
A CD4 lymphocyte count is a laboratory test that measures the number of CD4 T-cells (also known as CD4+ T-cells or helper T-cells) in a sample of blood. CD4 cells are a type of white blood cell that plays a crucial role in the body's immune response, particularly in fighting off infections caused by viruses and other pathogens.
CD4 cells express a protein on their surface called the CD4 receptor, which is used by human immunodeficiency virus (HIV) to infect and destroy these cells. As a result, people with HIV infection or AIDS often have low CD4 lymphocyte counts, which can make them more susceptible to opportunistic infections and other complications.
A normal CD4 lymphocyte count ranges from 500 to 1,200 cells per cubic millimeter of blood (cells/mm3) in healthy adults. A lower than normal CD4 count is often used as a marker for the progression of HIV infection and the development of AIDS. CD4 counts are typically monitored over time to assess the effectiveness of antiretroviral therapy (ART) and to guide clinical decision-making regarding the need for additional interventions, such as prophylaxis against opportunistic infections.
Oxazines are heterocyclic organic compounds that contain a six-membered ring with one nitrogen atom, one oxygen atom, and four carbon atoms. The structure of oxazine is similar to benzene, but with one methine group (=CH−) replaced by a nitrogen atom and another methine group replaced by an oxygen atom.
Oxazines have important applications in the pharmaceutical industry as they are used in the synthesis of various drugs, including anti-inflammatory, antiviral, and anticancer agents. However, oxazines themselves do not have a specific medical definition, as they refer to a class of chemical compounds rather than a medical condition or treatment.
Oligopeptides are defined in medicine and biochemistry as short chains of amino acids, typically containing fewer than 20 amino acid residues. These small peptides are important components in various biological processes, such as serving as signaling molecules, enzyme inhibitors, or structural elements in some proteins. They can be found naturally in foods and may also be synthesized for use in medical research and therapeutic applications.
Organophosphonates are a class of organic compounds characterized by the presence of a carbon-phosphorus bond. They contain a phosphonic acid group, which consists of a phosphorus atom bonded to four oxygen or nitrogen atoms, with one of those bonds being replaced by a carbon atom.
In a medical context, organophosphonates are commonly used as radiopharmaceuticals in diagnostic nuclear medicine procedures, such as bone scans. These compounds have the ability to bind to hydroxyapatite, the mineral component of bones, and can be labeled with radioactive isotopes for imaging purposes. They may also be used in therapeutic settings, including as treatments for conditions such as tumor-induced hypercalcemia and Paget's disease of bone.
It is important to note that organophosphonates are distinct from organophosphates, another class of compounds that contain a phosphorus atom bonded to three oxygen or sulfur atoms and one carbon atom. Organophosphates have been widely used as pesticides and chemical warfare agents, and can pose significant health risks due to their toxicity.
Lamivudine is an antiretroviral medication used in the treatment and management of HIV (Human Immunodeficiency Virus) infection and HBV (Hepatitis B Virus) infection. It is a nucleoside reverse transcriptase inhibitor (NRTI), which means it works by blocking the action of the reverse transcriptase enzyme that the viruses need to multiply. By doing this, Lamivudine helps to reduce the amount of the virus in the body, which in turn helps to slow down or prevent the damage that the virus can cause to the immune system and improve the patient's quality of life.
The medical definition of Lamivudine is: "A synthetic nucleoside analogue with activity against both HIV-1 and HBV. It is used in the treatment of HIV infection and AIDS, as well as chronic hepatitis B."
In the context of medical terminology, tablets refer to pharmaceutical dosage forms that contain various active ingredients. They are often manufactured in a solid, compressed form and can be administered orally. Tablets may come in different shapes, sizes, colors, and flavors, depending on their intended use and the manufacturer's specifications.
Some tablets are designed to disintegrate or dissolve quickly in the mouth, making them easier to swallow, while others are formulated to release their active ingredients slowly over time, allowing for extended drug delivery. These types of tablets are known as sustained-release or controlled-release tablets.
Tablets may contain a single active ingredient or a combination of several ingredients, depending on the intended therapeutic effect. They are typically manufactured using a variety of excipients, such as binders, fillers, and disintegrants, which help to hold the tablet together and ensure that it breaks down properly when ingested.
Overall, tablets are a convenient and widely used dosage form for administering medications, offering patients an easy-to-use and often palatable option for receiving their prescribed treatments.
Lipodystrophy is a medical condition characterized by abnormal distribution or absence of fat (adipose tissue) in the body. It can lead to metabolic complications such as insulin resistance, diabetes mellitus, high levels of fats in the blood (dyslipidemia), and liver disease. There are different types of lipodystrophy, including congenital generalized lipodystrophy, acquired generalized lipodystrophy, and partial lipodystrophy, which can affect different parts of the body and have varying symptoms and causes.
HIV (Human Immunodeficiency Virus) is a species of lentivirus (a subgroup of retrovirus) that causes HIV infection and over time, HIV infection can lead to AIDS (Acquired Immunodeficiency Syndrome). This virus attacks the immune system, specifically the CD4 cells, also known as T cells, which are a type of white blood cell that helps coordinate the body's immune response. As HIV destroys these cells, the body becomes more vulnerable to other infections and diseases. It is primarily spread through bodily fluids like blood, semen, vaginal fluids, and breast milk.
It's important to note that while there is no cure for HIV, with proper medical care, HIV can be controlled. Treatment for HIV is called antiretroviral therapy (ART). If taken as prescribed, this medicine reduces the amount of HIV in the body to a very low level, which keeps the immune system working and prevents illness. This treatment also greatly reduces the risk of transmission.
Lopinavir
Chloroquine and hydroxychloroquine during the COVID-19 pandemic
Parvesh Bhainswal
COVID-19 drug repurposing research
Ritonavir
Andy Harris (politician)
Umifenovir
Didier Raoult
Charles Flexner
AbbVie
Saquinavir
COVID-19 hospital
COVID-19 drug development
Protease inhibitor (pharmacology)
Treatment and management of COVID-19
Oxycodone
Ralph S. Baric
Thiomer
COVID-19 pandemic in Vietnam
Bupropion
Responses to the COVID-19 pandemic in May 2020
RECOVERY Trial
Pravastatin
Artemether
Colchicine
Martin Landray
COVID-19 pandemic in Bhutan
Etonogestrel
Camostat
Tipranavir
Lopinavir - Wikipedia
Lopinavir and Ritonavir: MedlinePlus Drug Information
Lopinavir/Ritonavir | AVAC
RCSB PDB - 1MUI: Crystal structure of HIV-1 protease complexed with Lopinavir.
Lopinavir - Janusinfo.se
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings | Thorax
Assessing the adoption of lopinavir/ritonavir oral pellets for HIV‐positive children in Zimbabwe | DNDi
Lopinavir/Ritonavir COVID-19 Treatment Linked to Bradycardia - Physician's Weekly
PDF) A Pilot Study of Switch to Lopinavir/Ritonavir (LPV/r) Monotherapy from Nonnucleoside Reverse Transcriptase Inhibitor...
Effects of 4 weeks of atazanavir, lopinavir/ritonavir, or placebo on endothelial function and insulin sensitivity in healthy men
Lopinavir/Ritonavir (Kaletra, LPV/r) | NIH
Effect of systemic inflammatory response to SARS-CoV-2 on lopinavir and hydroxychloroquine plasma concentrations. - Zurich...
Cipla gets US FDA approval for Lopinavir and ritonavir oral pellets - Express Pharma
Lopinavir /Ritonavir
Recomendación Lopinavir - Ritonavir
High Risk for Lopinavir Resistance After Sustained Treatment Failure - Infectious Disease Advisor
Lopinavir - Wikipedija, prosta enciklopedija
Kaletra (Lopinavir and ritonavir)
enzymes - How is the protease inhibited by lopinavir different in SARS-CoV-2 compared to SARS-CoV? - Biology Stack Exchange
COVID-19 Pulmonary Management: Practice Essentials, Pathogenesis of COVID-19, Clinical Features of COVID-19
Lopinavir-Ritonavir | Prescription Discount Pricing - OptionRx
lopinavir para mujeres - Life Enhancement Group
Lopinavir/ritonavir | Johns Hopkins ABX Guide
Coronavirus Treatment: Remdesivir & Other Drugs
achat lopinavir en espagne lopinavir achat - WAMRA
Lopinavir/ritonavir Singapore | Lopinavir/ritonavir | Shim Clinic
Buy Ritocom Tablet | Lopinavir and Ritonavir | 20% OFF
PANAX GINSENG: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews
LOPINAVIR 200mg RITONAVIR TABLETS 50mg Manufacturer in Gujarat - Best Price
Kaletra10
- Lopinavir / Ritonavir (Kaletra) Lopinavir / ritonavir is changed and broken down by the liver. (nih.gov)
- Lopinavir in fixed combination with ritonavir is available as tablets of 100 mg/25 mg and 200 mg/50 mg and as an oral solution (80/20 mg per mL) for pediatric use generically and under the brand name Kaletra. (nih.gov)
- Kaletra, a medicine containing two HIV drugs, lopinavir and ritonavir, which was considered as a potential treatment for the novel coronavirus was not effective, according to a China COVID-19, trial released recently in the New England Journal of Medicine . (pharma-industry-review.com)
- A study of extreme COVID-19 disease in Chinese patients showed that the 99 who received Kaletra (lopinavir/ritonavir) by US-headquartered biopharmaceutical company AbbVie Inc, a combination of lopinavir and ritonavir, did no better than the 100 who received standard treatment. (pharma-industry-review.com)
- Those who got the experimental COVID-19 Kaletra (lopinavir/ritonavir) treatment made slight improvements in time to clinical recovery and mortality at 28 days, although there was no statistically meaningful difference. (pharma-industry-review.com)
- The experimental Kaletra (lopinavir/ritonavir) COVID-19 therapy has been used by doctors in various countries in hopes of being effective. (pharma-industry-review.com)
- Lopinavir/ritonavir, the anti-HIV drug being tested, is most commonly sold under the name Kaletra. (dailymail.co.uk)
- The HIV drug Kaletra (generic names lopinavir and ritonavir) was studied early to great fanfare as a possible COVID-19 treatment. (emedicinehealth.com)
- Generic Kaletra contains a combination of lopinavir and ritonavir. (mydiscountpill.com)
- Lopinavir and ritonavir are antiviral medications that prevent human immunodeficiency virus (HIV) cells from multiplying in your body.Lopinavir and ritonavir (Kaletra) is a combination medicine used to treat HIV, which causes the acquired immunodeficiency syndrome (AIDS). (mydiscountpill.com)
Taking lopinavir and ritonavir2
- Do not stop taking lopinavir and ritonavir without talking to your doctor. (medlineplus.gov)
- If you miss doses, take less than the prescribed amount, or stop taking lopinavir and ritonavir, your condition may become more difficult to treat. (medlineplus.gov)
Combination of lopinavir and ritonavir2
- The combination of lopinavir and ritonavir is used with other medications to treat human immunodeficiency virus (HIV) infection. (medlineplus.gov)
- The combination of lopinavir and ritonavir comes as a tablet and a solution (liquid) to take by mouth. (medlineplus.gov)
Adding lopinavir-ritonavir treatment1
- The research team "did not find that adding lopinavir-ritonavir treatment reduced viral RNA loads or duration of viral RNA detectability "as compared with standard care alone. (pharma-industry-review.com)
Ritonavir and Lopinavir2
- Lopimune tablets, a combination of two HIV drugs, Ritonavir and Lopinavir, help control and slow down the HIV spread. (arrowmeds.com)
- The marketed drugs Ritonavir and Lopinavir had a MolDock score of -185.386 and -178.251, respectively. (ijpsr.com)
Severe COVID-192
- In 2020, lopinavir/ritonavir was found not to work in severe COVID-19. (wikipedia.org)
- In hospitalized adult patients with severe Covid-19, no benefit was observed with lopinavir-ritonavir treatment beyond standard care. (qxmd.com)
Hydroxychloroquine3
- Currently, there is no available treatment proven to be effective against COVID-19, but multiple agents, including lopinavir and ritonavir (L/R), remdesivir, chloroquine, hydroxychloroquine, ribavirin are used off label (3). (hvt-journal.com)
- Several points of concern arise regarding the methodology and the presented results of Discovery, the large French multicenter, randomized, controlled trial which evaluated the efficacy and safety of lopinavir + ritonavir (L/r), lopinavir/ritonavir + Interferon β-1a (L/r + IFN), and hydroxychloroquine (HCQ) in adults hospitalized for COVID-19. (fortunepublish.com)
- Solidarity trial interim results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in mortality of hospitalized COVID-19 patients (see link below). (who.int)
Antiretroviral8
- Lopinavir is an antiretroviral of the protease inhibitor class. (wikipedia.org)
- Lopinavir is an antiretroviral protease inhibitor used in combination with ritonavir in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS). (nih.gov)
- In HBV or HCV coinfected patients, highly active antiretroviral therapy with lopinavir may result of an exacerbation of the underlying chronic hepatitis B or C. (nih.gov)
- Some degree of serum aminotransferase elevations occur in a high proportion of patients taking lopinavir containing antiretroviral regimens. (nih.gov)
- In addition, initiation of lopinavir/ritonavir based highly active antiretroviral therapy can lead to exacerbation of an underlying chronic hepatitis B or C in coinfected individuals, typically arising 2 to 12 months after starting therapy, and associated with a hepatocellular pattern of serum enzyme elevations and increases in serum levels of hepatitis B virus (HBV) DNA or hepatitis C virus (HCV) RNA. (nih.gov)
- In patients with HBV or HCV coinfection, initiation of highly active antiretroviral therapy including lopinavir may be associated with flares of the underlying chronic hepatitis which are thought to be the result of reconstitution of the immune system, viral interactions or a direct effect of the drug on the hepatitis virus. (nih.gov)
- Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial. (bvsalud.org)
- The International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1060 study demonstrated short-term superiority of lopinavir / ritonavir (LPV/r) over nevirapine (NVP) in antiretroviral therapy ( ART ), regardless of prior NVP exposure. (bvsalud.org)
Protease inhibitor3
- It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir (lopinavir/ritonavir). (wikipedia.org)
- Lopinavir (loe pin' a vir) is a peptidomimetic HIV protease inhibitor that acts by binding to the catalytic site of the HIV protease, thereby preventing the cleavage of viral polyprotein precursors into mature, functional proteins that are necessary for viral replication. (nih.gov)
- Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppres" by S. Paskas, E. Mazzon et al. (hofstra.edu)
Nevirapine2
- A recent, scheduled interim data and safety review of a clinical study comparing anti-HIV treatment regimens based on either nevirapine (NVP) or ritonavir-boosted lopinavir (LPV/r) has found LPV/r to be more effective than NVP in HIV-infected children who received a single dose of NVP at birth. (nih.gov)
- For complete details on the finding, please visit Bulletin: Lopinavir Proves Superior to Nevirapine in HIV-Infected Infants Who Received Single-Dose Nevirapine at Birth . (nih.gov)
Pharmacokinetic1
- Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients. (cdc.gov)
Medication3
- When lopinavir and ritonavir are taken together, ritonavir also helps to increase the amount of lopinavir in the body so that the medication will have a greater effect. (medlineplus.gov)
- The lopinavir-ritonavir medication, "had no discernible effect" on virus replication which is how the therapy is designed to work. (pharma-industry-review.com)
- LOPIKAST is a medication made by combining lopinavir and ritonavir. (mydrughouse.com)
Coronavirus2
- Lopinavir and ritonavir are currently being studied in several ongoing clinical studies for the treatment of coronavirus disease 2019 (COVID-19) either alone or with other medications. (medlineplus.gov)
- The research was carried out to find a potential drug that could inhibit the action of coronavirus, and drugs such as Lopinavir, and Ritonavir derivatives were taken as standards. (ijpsr.com)
Infection1
- Lopinavir was approved for use in the United States in 2000 for the treatment of HIV infection in adults and children. (nih.gov)
Called protease inhibitors1
- Lopinavir and ritonavir are in a class of medications called protease inhibitors. (medlineplus.gov)
Pharmacokinetics3
- Lopinavir is usually given in combination with low "booster" doses of ritonavir which improves the pharmacokinetics of lopinavir by slowing its hepatic metabolism. (nih.gov)
- CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. (cdc.gov)
- Pharmacogenetic analysis of SNPs in genes involved in the pharmacokinetics and response to lopinavir/ritonavir therapy. (cdc.gov)
Tablets2
- tell your doctor and pharmacist if you are allergic to lopinavir, ritonavir (Norvir), any other medications, or any of the ingredients in lopinavir and ritonavir tablets or solution. (medlineplus.gov)
- The dosage of LOPIKAST tablets (lopinavir 200 mg and ritonavir 50 mg) should be taken at the same time every day. (mydrughouse.com)
FLARE1
- Rewrote recentralizing its flare Bromphen imaginably, an permutationist rubs anything precervicalis buy cheap lopinavir usa price belfast inapprehensive buy cheap lopinavir usa price belfast unless pelting coatis. (gunslingerlongboards.co.za)
Infants and young children1
- The big news since the 2014 Pipeline Report is that there is finally a solid form of lopinavir/ritonavir (LPV/r) suitable for infants and young children. (treatmentactiongroup.org)
Dose2
- Although lopinavir has been associated with impaired adrenal gland function when given directly to infants, the effect is dose related. (nih.gov)
- Lopimune consists of a combination dose of Lopinavir and Ritonavir. (arrowmeds.com)
Clinical trial1
- This case highlights off-label prescribing lopinavir/ritonavir outside of a clinical trial setting should be avoided until the data have proven that treatment benefit over placebo. (hvt-journal.com)
Concentration2
Adults1
- The recommended dosage of lopinavir in adults is 800 mg daily in combination with 200 mg of ritonavir, either once daily or in two divided doses. (nih.gov)
Patients9
- however, a study of paired CSF-plasma samples from 26 patients receiving lopinavir/ritonavir found lopinavir CSF levels above the IC50 in 77% of samples. (wikipedia.org)
- The patients were randomly assigned in a 1:1 ratio to receive either lopinavir-ritonavir (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care, or just standard care. (pharma-industry-review.com)
- SARS-CoV-2 RNA was still detected in 40.7% of the patients in the lopinavir-ritonavir group at the end of the trial (day 28). (pharma-industry-review.com)
- The combination of lopinavir-ritonavir also caused adverse side effects, primarily gastrointestinal, in almost 14% of the patients and had to be discontinued. (pharma-industry-review.com)
- The lopinavir-ritonavir combination also produced more side effects, prompting the treatments to be halted in 13.8% of patients. (pharma-industry-review.com)
- In a post hoc subgroup analysis, the death rate difference between the lopinavir-ritonavir group and the standard-care group was observed to be higher among patients treated within 12 days after the onset of symptoms than among those treated later. (pharma-industry-review.com)
- Lopinavir-ritonavir treatment was stopped early in 13 patients (13.8%) because of adverse events. (qxmd.com)
- Chloroquine, an anti-malarial drug, and HIV-suppressing combination lopinavir/ritonavir have both reportedly shown promising results in human tests and made the virus 'disappear' in infected patients. (dailymail.co.uk)
- But patients in the lopinavir/ritonavir group had a shorter stay in the intensive care unit than did those in the standard-care group. (the-hospitalist.org)
Efficacy1
- Depending on the efficacy and tolerance of lopinavir and ritonavir. (msf.org)
Adverse2
Oral1
- lopinavir/ritonavir) oral solution. (wikipedia.org)
Benefit1
- The research team is now questioning if earlier lopinavir-ritonavir treatment in COVID-19 could have clinical benefit. (pharma-industry-review.com)
Liver5
- to affect how quickly the liver breaks down lopinavir / ritonavir in humans. (nih.gov)
- Lopinavir can cause transient and usually asymptomatic elevations in serum aminotransferase levels and, rarely, clinically apparent, acute liver injury. (nih.gov)
- Clinically apparent liver disease due to lopinavir/ritonavir occurs, but is rare. (nih.gov)
- Lopinavir therapy has not been clearly linked to lactic acidosis and acute fatty liver that is reported in association with several nucleoside analogue reverse transcriptase inhibitors. (nih.gov)
- The cause of the clinical hepatotoxicity from lopinavir may be due to its metabolism by the liver, which is largely by the cytochrome P450 system (CYP3A4), which may result in production of a toxic intermediate. (nih.gov)
Medications2
- Although lopinavir and ritonavir will not cure HIV, these medications may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. (medlineplus.gov)
- Your doctor will probably tell you not to take lopinavir and ritonavir if you are taking one or more of these medications. (medlineplus.gov)
Treatment4
- The use of lopinavir and ritonavir for the treatment of COVID-19 has not yet been established. (medlineplus.gov)
- Lopinavir and ritonavir should be taken ONLY under the direction of a doctor for the treatment of COVID-19. (medlineplus.gov)
- Patient was successfully treated by temporary pacemaker, normal sinus rhythm was reverted on a 3rd day after stopping the lopinavir/ritonavir treatment. (hvt-journal.com)
- Bradyarrhythmia in form of sinus arrest can develop during treatment with lopinavir/ritonavir. (hvt-journal.com)
Serum1
- Lopinavir appears in breastmilk in low levels and can be found in the serum of some breastfed infants. (nih.gov)
Replication1
- Lopinavir was found to inhibit MERS-CoV replication in the low-micromolar range in cell cultures. (wikipedia.org)
Medicines1
- Serious drug interactions can occur when certain medicines are used together with lopinavir and ritonavir. (mydiscountpill.com)
Daily1
- Lopinavir/ritonavir 800mg/200 mg, daily was started. (hvt-journal.com)
Standard-care group1
- 99 were assigned to the lopinavir-ritonavir group, and 100 to the standard-care group. (qxmd.com)
Https2
- 2023. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545123/all/Lopinavir_ritonavir. (hopkinsguides.com)
- 2023. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540322/all/Lopinavir_ritonavir. (unboundmedicine.com)
Show1
- S1 show quasi-brotherly "usa cheap buy belfast lopinavir price" acomiadedicational before zabaione aside itself danaea. (gunslingerlongboards.co.za)
Effect1
- Lopinavir has been shown to impair protein synthesis via AMP-activated protein kinase (AMPK) and eEF2 kinase (eEF2K) activation, a mechanism that is similar to the antiviral effect of protein phosphatase 1 inhibitors. (wikipedia.org)
Study1
- A 2014 study indicates that lopinavir is effective against the human papilloma virus (HPV). (wikipedia.org)